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      Median (range) 74 (32-86)
Sex
      Male 7 58
      Female 5 42
Clinical Characteristic N %
Prior Therapy
      Radiation therapy 6 50
      Chemotherapy/targeted therapy* 6 50
      High-dose interleukin-2 (IL-2) 5 42
      Resection/debulking 3 25
      Interferon alpha 2 17
      Amputation 1 8
      Gamma knife 1 8
      GM-CSF 1 8
      Other therapies 3 25
No. of Metastatic Sites
      <3 1 8
      3-5 9 75
      6-10 1 8
      >10 1 8
*Included one or more of the following agents: temozolomide, 
thalidomide, paclitaxel, carboplatin, sorafenib.
Table 2. Clinical Characteristics
Purpose
•		The	primary	objective	of	this	study	was	to	evaluate	the	safety	and	toxicity	
of	Cadi-05	monotherapy	in	the	treatment	of	advanced	melanoma	patients.
